Lv1
18 积分 2023-03-02 加入
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
11小时前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
11小时前
已完结
First‐in‐human study of HDM1002, a GLP‐1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers
1天前
已完结
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
1个月前
已完结
Safety of Technosphere Inhaled Insulin
11个月前
已完结
Bilayer channel structure to improve the stability of solution-processed metal oxide transistors under AC stress
1年前
已完结
Less invasive surfactant administration methods: Who, what and how
1年前
已完结
GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models
1年前
已完结
Nintedanib as the First Treatment for Group of Progressive Interstitial Lung Diseases: A Review of Patent Literature
1年前
已关闭
皖公网安备34019202002308
